Levetiracetam in the prophylaxis of migraine with aura: A 6-month open-label study

Clinical Neuropharmacology

Volumn 29, Issue 6, 2006, Pages 338-342

  Brighina, Filippo ^a   Palermo, Antonio ^a   Aloisio, Antonina ^b   Francolini, Margherita ^a   Giglia, Giuseppe ^a   Fierro, Brigida ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Civic Hospital   (Italy)

Author keywords

Aura; Levetiracetam; Migraine; Prophylaxis

Indexed keywords

ETIRACETAM;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MIGRAINE AURA; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; PIRACETAM; PROSPECTIVE STUDIES;

EID: 33750918330     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000236766.08409.03     Document Type: Article

References (18)

1. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-552.
2. Ferrari MD, Haan J. The genetics of migraine: implication for treatment approaches. J Neural Transm Suppl 2002;63:111-127.
3. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142.
4. Sandor PS, Mascia A, Seidel L, et al. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol 2001;49:668-672.
5. Ambrosini A, Maertens de Noordhout A, Schoenen J. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology 2001;56:1038-1043.
6. D'Andrea G, Granella F, Cadaldini M, et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999;19:64-66.
7. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001;306:5-8.
8. Zona C, Niespodziany I, Marchetti C, et al. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001;10:279-286.
9. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
10. Richter F, Ebersberger A, Schaible HG. Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci Lett 2002;334:123-126.
11. Ebersberger A, Portz S, Meissner W, et al. Effects of N-, P/Q- and L-type calcium channel blockers on nociceptive neurones of the trigeminal nucleus with input from the dura. Cephalalgia 2004;24:250-261.
12. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):1-151.
13. Cochran JW. Levetiracetam as migraine prophylaxis. Clin J Pain 2004;20:198-199.
14. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004;44:238-243.
15. Drake ME, Greathouse MI, Armentbright AD, et al. Levetiracetam for preventive treatment of migraine. Cephalalgia 2001;21:373. [abstract].
16. Kruscz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 2001;21:373. [abstract].
17. Troost BT, Wiles RM. Two-phase open-label study of levetiracetam in the management of intractable headache. Paper presented at: Diamond Headache Meeting; January 11-15, 2003; Rancho Mirage, CA.
18. Turner IM, Entin EJ, Newman SM, Agrillo T. Levetiracetam for migraine prophylaxis. Paper presented at: Diamond Headache Meeting; July 15-19, 2003; Buena Vista, FL.